{"disease":{"id":"acute-myeloid-leukemia-with-myelodysplasia-related-changes","name":"acute myeloid leukemia with myelodysplasia related changes"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00416598","title":"Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":546,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06143839","title":"VYxeoS Liposomal Italian Observational Study iN the Real Practice","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03330821","title":"Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03526926","title":"A Post-Marketing Observational Study of VYXEOS™","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT03128359","title":"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02935361","title":"Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT04231851","title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of California, Irvine","has_results":true},{"nct_id":"NCT04269213","title":"CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03146871","title":"Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03537599","title":"Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Sumithira Vasu","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}